Akero to Present Prelim Phase 2 Data on Cirrhosis Due to MASH Therapy

 Investor webcast on Monday, January 27, 2025, at 8:00 a.m. ET to present clinical data

 Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, will hold an investor conference on Monday, January 27, 2025, at 8:00 a.m. ET to share preliminary topline week 96 results from its SYMMETRY study, a double-blind, placebo-controlled Phase 2b study evaluating the efficacy of efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to metabolic dysfunction-associated steatohepatitis (MASH).

Conference Call / Webcast Details
The company will host a conference call and webcast with slide presentation at 8:00 a.m. ET on Monday, January 27. Please click here to register for the event. The live webcast will be available on the Events & Presentations page of the Akero website, with the recording and presentation available immediately following the event.

https://www.globenewswire.com/news-release/2025/01/24/3015109/0/en/Akero-Therapeutics-to-Present-Preliminary-Topline-Week-96-Results-from-Phase-2b-SYMMETRY-Study-Investigating-Efruxifermin-in-Patients-with-Compensated-Cirrhosis-F4-Due-to-MASH.html